In the context of the pandemic, this year’s CIIE, the medical equipment and medicine and health care exhibition area has become one of the most popular exhibition areas. Many multinational medical and pharmaceutical companies have brought innovative medicines and medical devices that are “the world’s first exhibition in China”, and have also announced plans to accelerate investment in China. The series of reports “Global CEOs Watch Jinbo” Today (9th) reporters interviewed Zhang Xiao, senior vice president and president of Greater China of Wari Safety Ball, and Shan Guohong, senior vice president of Takeda Pharmaceuticals and President of Takeda China.
Varian, a medical system company from the United States, occupies more than half of the global tumor radiotherapy market. Zhang Xiao said that after the CIIE last year, he deeply felt that the exhibits are accelerating the conversion into commodities.
Encouraged by the spillover effect of the CIIE, Varian brought five major anti-cancer weapons this year, including China’s first upgraded version of the “Speed Knife” that can accurately strike tumors in various parts of the body, and the “Speed Knife” that can be delivered to the vicinity of the tumor to release the drug effect “Ultra-fine bomb” embolizes drug-loaded microspheres.
Takeda Pharmaceuticals, a multinational pharmaceutical company with a history of 239 years and a deep cultivation in China for more than 20 years, brought a 750-square-meter double booth at this year’s CIIE to showcase a rich product pipeline in core areas such as oncology, digestion, rare diseases, and blood products.
During the pandemic, many multinational pharmaceutical companies made additional investments in China, including Varian and Takeda Pharmaceuticals. In March of this year, the first Chinese-made high-end medical linear accelerator, TrueBeam, rolled off the production line. This is the newly added production line of the Varian Beijing base this year, marking that the Beijing base surpassed the Silicon Valley base of the group headquarters and became the most complete product line of the Varian safety ball. R&D and production base.
In September of this year, Takeda’s Tianjin factory with an investment of 110 million yuan was officially completed. It will focus on the production of drugs in the oncology and digestive fields, and accelerate the production and supply of innovative drugs. It is estimated that in the next five years, Takeda will market more than 15 innovative drugs in China, benefiting more than 10 million Chinese patients, and becoming one of the multinational pharmaceutical companies with the most new products on the market.
